Efficacy of CD34+ stem cell therapy in nonischemic dilated cardiomyopathy is absent in patients with diabetes but preserved in patients with insulin resistance

Bojan Vrtovec, Matjaz Sever, Mojca Jensterle, Gregor Poglajen, Andrej Janez, Nika Kravos, Gregor Zemljic, Marko Cukjati, Peter Cernelc, François Haddad, Joseph C. Wu, Ulrich P. Jorde

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We evaluated the association of diabetes and insulin resistance with the response to cell therapy in patients with nonischemic dilated cardiomyopathy (DCM). A total of 45 outpatients with DCM received granulocyte colony-stimulating factor for 5 days. CD34+ cells were then collected by apheresis and injected transendocardially. Twelve patients had diabetes mellitus (DM group), 17 had insulin resistance (IR group), and 16 displayed normal glucose metabolism (no-IR group). After stimulation, we found higher numbers of CD34+ cells in the IR group (94 ± 73×106 cells per liter) than in the no-IR group (54 ± 35 × 106 cells per liter) or DM group (31 ± 20 × 106 cells per liter; p =.005). Similarly, apheresis yielded the highest numbers of CD34+ cells in the IR group (IR group, 21661103106 cells; no-IR group, 127 ± 82 × 106 cells;DMgroup, 77 ± 83×106 cells; p =.002). Six months after cell therapy, we found an increase in left ventricular ejection fraction in the IR group (+5.6%66.9%) and the no-IR group (+4.4% 6 7.2%) but not in the DM group (20.9% 6 5.4%; p =.035). The N-terminal probrain natriuretic peptide levels decreased in the IR and no-IR groups, but not in theDMgroup (-606 ± 850 pg/ml; -698 ± 1,105 pg/ml; and +238 ± 963 pg/ml, respectively; p =.034). Transendocardial CD34+ cell therapy appears to be ineffective in DCM patients with diabetes. IR was associated with improved CD34+ stem cell mobilization and a preserved clinical response to cell therapy.

Original languageEnglish (US)
Pages (from-to)632-638
Number of pages7
JournalStem cells translational medicine
Volume5
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Dilated Cardiomyopathy
Cell- and Tissue-Based Therapy
Insulin Resistance
Stem Cells
Blood Component Removal
Cell Count
Hematopoietic Stem Cell Mobilization
Natriuretic Peptides
Granulocyte Colony-Stimulating Factor
Stroke Volume
Diabetes Mellitus
Outpatients
Glucose

Keywords

  • Diabetes
  • Dilated cardiomyopathy
  • Insulin resistance
  • Stem cells

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

Efficacy of CD34+ stem cell therapy in nonischemic dilated cardiomyopathy is absent in patients with diabetes but preserved in patients with insulin resistance. / Vrtovec, Bojan; Sever, Matjaz; Jensterle, Mojca; Poglajen, Gregor; Janez, Andrej; Kravos, Nika; Zemljic, Gregor; Cukjati, Marko; Cernelc, Peter; Haddad, François; Wu, Joseph C.; Jorde, Ulrich P.

In: Stem cells translational medicine, Vol. 5, No. 5, 2016, p. 632-638.

Research output: Contribution to journalArticle

Vrtovec, B, Sever, M, Jensterle, M, Poglajen, G, Janez, A, Kravos, N, Zemljic, G, Cukjati, M, Cernelc, P, Haddad, F, Wu, JC & Jorde, UP 2016, 'Efficacy of CD34+ stem cell therapy in nonischemic dilated cardiomyopathy is absent in patients with diabetes but preserved in patients with insulin resistance', Stem cells translational medicine, vol. 5, no. 5, pp. 632-638. https://doi.org/10.5966/sctm.2015-0172
Vrtovec, Bojan ; Sever, Matjaz ; Jensterle, Mojca ; Poglajen, Gregor ; Janez, Andrej ; Kravos, Nika ; Zemljic, Gregor ; Cukjati, Marko ; Cernelc, Peter ; Haddad, François ; Wu, Joseph C. ; Jorde, Ulrich P. / Efficacy of CD34+ stem cell therapy in nonischemic dilated cardiomyopathy is absent in patients with diabetes but preserved in patients with insulin resistance. In: Stem cells translational medicine. 2016 ; Vol. 5, No. 5. pp. 632-638.
@article{ab812909ef2d48b99f5b84572ffce0b0,
title = "Efficacy of CD34+ stem cell therapy in nonischemic dilated cardiomyopathy is absent in patients with diabetes but preserved in patients with insulin resistance",
abstract = "We evaluated the association of diabetes and insulin resistance with the response to cell therapy in patients with nonischemic dilated cardiomyopathy (DCM). A total of 45 outpatients with DCM received granulocyte colony-stimulating factor for 5 days. CD34+ cells were then collected by apheresis and injected transendocardially. Twelve patients had diabetes mellitus (DM group), 17 had insulin resistance (IR group), and 16 displayed normal glucose metabolism (no-IR group). After stimulation, we found higher numbers of CD34+ cells in the IR group (94 ± 73×106 cells per liter) than in the no-IR group (54 ± 35 × 106 cells per liter) or DM group (31 ± 20 × 106 cells per liter; p =.005). Similarly, apheresis yielded the highest numbers of CD34+ cells in the IR group (IR group, 21661103106 cells; no-IR group, 127 ± 82 × 106 cells;DMgroup, 77 ± 83×106 cells; p =.002). Six months after cell therapy, we found an increase in left ventricular ejection fraction in the IR group (+5.6{\%}66.9{\%}) and the no-IR group (+4.4{\%} 6 7.2{\%}) but not in the DM group (20.9{\%} 6 5.4{\%}; p =.035). The N-terminal probrain natriuretic peptide levels decreased in the IR and no-IR groups, but not in theDMgroup (-606 ± 850 pg/ml; -698 ± 1,105 pg/ml; and +238 ± 963 pg/ml, respectively; p =.034). Transendocardial CD34+ cell therapy appears to be ineffective in DCM patients with diabetes. IR was associated with improved CD34+ stem cell mobilization and a preserved clinical response to cell therapy.",
keywords = "Diabetes, Dilated cardiomyopathy, Insulin resistance, Stem cells",
author = "Bojan Vrtovec and Matjaz Sever and Mojca Jensterle and Gregor Poglajen and Andrej Janez and Nika Kravos and Gregor Zemljic and Marko Cukjati and Peter Cernelc and Fran{\cc}ois Haddad and Wu, {Joseph C.} and Jorde, {Ulrich P.}",
year = "2016",
doi = "10.5966/sctm.2015-0172",
language = "English (US)",
volume = "5",
pages = "632--638",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Efficacy of CD34+ stem cell therapy in nonischemic dilated cardiomyopathy is absent in patients with diabetes but preserved in patients with insulin resistance

AU - Vrtovec, Bojan

AU - Sever, Matjaz

AU - Jensterle, Mojca

AU - Poglajen, Gregor

AU - Janez, Andrej

AU - Kravos, Nika

AU - Zemljic, Gregor

AU - Cukjati, Marko

AU - Cernelc, Peter

AU - Haddad, François

AU - Wu, Joseph C.

AU - Jorde, Ulrich P.

PY - 2016

Y1 - 2016

N2 - We evaluated the association of diabetes and insulin resistance with the response to cell therapy in patients with nonischemic dilated cardiomyopathy (DCM). A total of 45 outpatients with DCM received granulocyte colony-stimulating factor for 5 days. CD34+ cells were then collected by apheresis and injected transendocardially. Twelve patients had diabetes mellitus (DM group), 17 had insulin resistance (IR group), and 16 displayed normal glucose metabolism (no-IR group). After stimulation, we found higher numbers of CD34+ cells in the IR group (94 ± 73×106 cells per liter) than in the no-IR group (54 ± 35 × 106 cells per liter) or DM group (31 ± 20 × 106 cells per liter; p =.005). Similarly, apheresis yielded the highest numbers of CD34+ cells in the IR group (IR group, 21661103106 cells; no-IR group, 127 ± 82 × 106 cells;DMgroup, 77 ± 83×106 cells; p =.002). Six months after cell therapy, we found an increase in left ventricular ejection fraction in the IR group (+5.6%66.9%) and the no-IR group (+4.4% 6 7.2%) but not in the DM group (20.9% 6 5.4%; p =.035). The N-terminal probrain natriuretic peptide levels decreased in the IR and no-IR groups, but not in theDMgroup (-606 ± 850 pg/ml; -698 ± 1,105 pg/ml; and +238 ± 963 pg/ml, respectively; p =.034). Transendocardial CD34+ cell therapy appears to be ineffective in DCM patients with diabetes. IR was associated with improved CD34+ stem cell mobilization and a preserved clinical response to cell therapy.

AB - We evaluated the association of diabetes and insulin resistance with the response to cell therapy in patients with nonischemic dilated cardiomyopathy (DCM). A total of 45 outpatients with DCM received granulocyte colony-stimulating factor for 5 days. CD34+ cells were then collected by apheresis and injected transendocardially. Twelve patients had diabetes mellitus (DM group), 17 had insulin resistance (IR group), and 16 displayed normal glucose metabolism (no-IR group). After stimulation, we found higher numbers of CD34+ cells in the IR group (94 ± 73×106 cells per liter) than in the no-IR group (54 ± 35 × 106 cells per liter) or DM group (31 ± 20 × 106 cells per liter; p =.005). Similarly, apheresis yielded the highest numbers of CD34+ cells in the IR group (IR group, 21661103106 cells; no-IR group, 127 ± 82 × 106 cells;DMgroup, 77 ± 83×106 cells; p =.002). Six months after cell therapy, we found an increase in left ventricular ejection fraction in the IR group (+5.6%66.9%) and the no-IR group (+4.4% 6 7.2%) but not in the DM group (20.9% 6 5.4%; p =.035). The N-terminal probrain natriuretic peptide levels decreased in the IR and no-IR groups, but not in theDMgroup (-606 ± 850 pg/ml; -698 ± 1,105 pg/ml; and +238 ± 963 pg/ml, respectively; p =.034). Transendocardial CD34+ cell therapy appears to be ineffective in DCM patients with diabetes. IR was associated with improved CD34+ stem cell mobilization and a preserved clinical response to cell therapy.

KW - Diabetes

KW - Dilated cardiomyopathy

KW - Insulin resistance

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84964258855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964258855&partnerID=8YFLogxK

U2 - 10.5966/sctm.2015-0172

DO - 10.5966/sctm.2015-0172

M3 - Article

VL - 5

SP - 632

EP - 638

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 5

ER -